{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T03:08:32Z","timestamp":1780628912672,"version":"3.54.1"},"reference-count":18,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,4,29]],"date-time":"2021-04-29T00:00:00Z","timestamp":1619654400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100013733","name":"Ipsen Biopharmaceuticals Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013733","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacejournalendocrinepractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrine Practice"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.eprac.2021.04.412","type":"journal-article","created":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T03:04:28Z","timestamp":1619838268000},"page":"1034-1039","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Health Benefit Costs and Absenteeism Among Employed Patients With Acromegaly"],"prefix":"10.1016","volume":"27","author":[{"given":"Kevin C.J.","family":"Yuen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn A.","family":"Munoz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard A.","family":"Brook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian A.","family":"Beren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John D.","family":"Whalen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas J.","family":"Rohrbacker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"Antonio","family":"Ribeiro-Oliveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.eprac.2021.04.412_bib1","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/s41574-018-0058-5","article-title":"A\u00a0consensus statement on acromegaly therapeutic outcomes","volume":"14","author":"Melmed","year":"2018","journal-title":"Nat Rev Endocrinol"},{"issue":"11","key":"10.1016\/j.eprac.2021.04.412_bib2","doi-asserted-by":"crossref","first-page":"3189","DOI":"10.1172\/JCI39375","article-title":"Acromegaly pathogenesis and treatment","volume":"119","author":"Melmed","year":"2009","journal-title":"J\u00a0Clin Invest"},{"issue":"1","key":"10.1016\/j.eprac.2021.04.412_bib3","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1007\/s11102-016-0754-x","article-title":"Epidemiology of acromegaly: review of population studies","volume":"20","author":"Lavrentaki","year":"2017","journal-title":"Pituitary"},{"issue":"4","key":"10.1016\/j.eprac.2021.04.412_bib4","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1007\/s11154-020-09588-z","article-title":"Multidisciplinary management of acromegaly: a consensus","volume":"21","author":"Giustina","year":"2020","journal-title":"Rev Endocr Metab Disord"},{"issue":"suppl 4","key":"10.1016\/j.eprac.2021.04.412_bib5","first-page":"1","article-title":"American Association of Clinical Endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of acromegaly\u20142011 update","volume":"17","author":"Katznelson","year":"2011","journal-title":"Endocr Pract"},{"issue":"1","key":"10.1016\/j.eprac.2021.04.412_bib6","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s40360-017-0124-y","article-title":"Treatment adherence and persistence with long-acting somatostatin analog therapy for the treatment of acromegaly: a retrospective analysis","volume":"18","author":"Gurel","year":"2017","journal-title":"BMC Pharmacol Toxicol"},{"issue":"4","key":"10.1016\/j.eprac.2021.04.412_bib7","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/s40618-018-0928-7","article-title":"Use of administrative health databases to estimate incidence and prevalence of acromegaly in Piedmont Region","volume":"42","author":"Caputo","year":"2019","journal-title":"Italy. J Endocrinol Invest."},{"issue":"3","key":"10.1016\/j.eprac.2021.04.412_bib8","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s40801-015-0039-0","article-title":"Treatment patterns and economic burden in patients treated for acromegaly in the USA","volume":"2","author":"Chuang","year":"2015","journal-title":"Drugs\u2013Real World Outcomes"},{"issue":"3","key":"10.1016\/j.eprac.2021.04.412_bib9","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1007\/s11102-015-0701-2","article-title":"Incidence and prevalence of acromegaly in a large US health plan database","volume":"19","author":"Burton","year":"2016","journal-title":"Pituitary"},{"issue":"5","key":"10.1016\/j.eprac.2021.04.412_bib10","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1185\/03007995.2015.1125870","article-title":"Patterns of pharmacologic treatment in US patients with acromegaly","volume":"32","author":"Broder","year":"2016","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.eprac.2021.04.412_bib12","author":"Hotfelder"},{"issue":"1","key":"10.1016\/j.eprac.2021.04.412_bib13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.17848\/1075-8445.9(1)-1","article-title":"Is compensation for workplace injuries adequate?","volume":"9","author":"Hunt","year":"2002","journal-title":"Employ Res"},{"issue":"1","key":"10.1016\/j.eprac.2021.04.412_bib17","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1097\/00005650-199801000-00004","article-title":"Comorbidity measures for use with administrative data","volume":"36","author":"Elixhauser","year":"1998","journal-title":"Med Care"},{"issue":"6","key":"10.1016\/j.eprac.2021.04.412_bib18","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1097\/JOM.0b013e31805776e6","article-title":"Employer benefit design considerations for the era of biotech drugs","volume":"49","author":"Vogenberg","year":"2007","journal-title":"J\u00a0Occup Environ Med"},{"issue":"12","key":"10.1016\/j.eprac.2021.04.412_bib19","first-page":"1106","article-title":"Clinical and economic burden of commercially insured patients with acromegaly in the United States: a retrospective analysis","volume":"21","author":"Placzek","year":"2015","journal-title":"J\u00a0Manag Care Spec Pharm"},{"issue":"1","key":"10.1016\/j.eprac.2021.04.412_bib20","first-page":"432","article-title":"Burden of acromegaly in the United States: increased health services utilization, location of care, and costs of care","volume":"24","author":"Ribeiro-Oliveira","year":"2021","journal-title":"J\u00a0Med Econ"},{"issue":"4","key":"10.1016\/j.eprac.2021.04.412_bib21","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s11102-013-0506-0","article-title":"Treatments, complications, and healthcare utilization associated with acromegaly: a study in two large United States databases","volume":"17","author":"Broder","year":"2014","journal-title":"Pituitary"},{"issue":"4","key":"10.1016\/j.eprac.2021.04.412_bib22","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1007\/s10926-018-9815-5","article-title":"Using predictive analytics for early identification of short-term disability claimants who exhaust their benefits","volume":"28","author":"Contreary","year":"2018","journal-title":"J\u00a0Occup Rehabil"}],"container-title":["Endocrine Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X21005711?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X21005711?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T22:10:29Z","timestamp":1761516629000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1530891X21005711"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":18,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["S1530891X21005711"],"URL":"https:\/\/doi.org\/10.1016\/j.eprac.2021.04.412","relation":{},"ISSN":["1530-891X"],"issn-type":[{"value":"1530-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Health Benefit Costs and Absenteeism Among Employed Patients With Acromegaly","name":"articletitle","label":"Article Title"},{"value":"Endocrine Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eprac.2021.04.412","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 AACE. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}